Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations

被引:21
|
作者
Bergman, Scott J. [1 ]
Speil, Cristian
Short, Michael
Koirala, Janak
机构
[1] So Illinois Univ, Sch Pharm, Dept Pharm Practice, Edwardsville, IL 62026 USA
[2] So Illinois Univ, Sch Med, Div Infect Dis, Springfield, IL USA
[3] Mem Med Ctr, Dept Pharm Serv, Springfield, IL 62781 USA
关键词
D O I
10.1016/j.idc.2007.07.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The study of pharmacokinetics includes the absorption, distribution, metabolism, and elimination of drugs. The pharmacologic effect that a medication has on the body is known as pharmacodynamics. With antimicrobials, pharmacokinetic and pharmacodynamic parameters become especially important because of the association between host drug concentrations, microorganism eradication, and resistance. This article focuses on the pharmacokinetic changes that can occur with antimicrobials when they are used in patients at high risk of infections and how they influence pharmacodynamic effects. The populations described here include patients with obesity and diabetes mellitus, renal or hepatic failure, chronic lung disease, severe burns, and long-term prosthetic devices and the elderly.
引用
收藏
页码:821 / +
页数:27
相关论文
共 50 条
  • [1] Pharmacokinetic and pharmacodynamic aspects in antibiotic treatment
    Bellmann, R.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2014, 109 (03) : 162 - 166
  • [2] Pharmacokinetic and Pharmacodynamic Considerations of Antibiotic Use in Neonates
    Regazzi, Mario
    Berardi, Alberto
    Picone, Simonetta
    Tzialla, Chryssoula
    ANTIBIOTICS-BASEL, 2023, 12 (12):
  • [3] Tobacco Use in High-Risk Populations
    Compton, Wilson M.
    Einstein, Emily B.
    JAMA NETWORK OPEN, 2020, 3 (03)
  • [4] Psychological aspects of cancer screening in high-risk populations
    Kash, KM
    Dabney, MR
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (05): : 519 - 524
  • [5] Use of pharmacokinetic/pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics
    Agoram, Balaji M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (02) : 153 - 160
  • [6] Practical aspects of antibiotic prophylaxis in high-risk surgical patients
    Sganga, G
    Brisinda, G
    Castagneto, M
    INFECTIONS IN THE CRITICALLY ILL: AN ONGOING CHALLENGE, 2001, : 47 - 58
  • [7] CONDOM USE AND USE-EFFECTIVENESS IN HIGH-RISK POPULATIONS
    DARROW, WW
    SEXUALLY TRANSMITTED DISEASES, 1989, 16 (03) : 157 - 160
  • [8] Antibiotic eluting envelopes: evidence, technology, and defining high-risk populations
    Callahan, Thomas D.
    Tarakji, Khaldoun G.
    Wilkoff, Bruce L.
    EUROPACE, 2021, 23 : 28 - 32
  • [9] Use of the Wearable Cardioverter Defibrillator in High-Risk Populations
    Madhab Lamichhane
    Abdul Safadi
    Phani Surapaneni
    Negar Salehi
    Ranjan K. Thakur
    Current Cardiology Reports, 2016, 18
  • [10] Use of the Wearable Cardioverter Defibrillator in High-Risk Populations
    Lamichhane, Madhab
    Safadi, Abdul
    Surapaneni, Phani
    Salehi, Negar
    Thakur, Ranjan K.
    CURRENT CARDIOLOGY REPORTS, 2016, 18 (08)